Board of Directors

Peter Barrett (Chairman)
Peter Barrett is a partner at Atlas Venture and has been involved in the creation of several novel therapeutic and drug discovery platform companies. He is also a Senior Fellow at Harvard Business School, where he teaches Commercializing Science to second year MBA students and is the faculty chair of the key advisory board of the Blavatnik Fellowship Program.

Peter is currently chairman of Zafgen (NASDAQ:ZFGN), Synlogic (NASDAQ:SYBX), Cadent Therapeutics and Obsidian Therapeutics, and also serves on the board of Indalo Therapeutics. He previously served on the boards of past Atlas companies Vitae Pharmaceuticals (NASDAQ:VTAE; acquired by Allergan), Stromedix (acquired by Biogen), Novamed (acquired by Sciclone), Alnylam (NASDAQ:ALNY), Harbour Antibodies (acquired by Harbour Biomed), Momenta (NASDAQ:MNTA), Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), Infacare (acquired by Mallinckrodt), Archemix (acquired by Baxter) and a number of other ventures.

Prior to joining Atlas Peter was co-founder, executive vice president, and chief business officer of Celera Genomics, which announced the first successful sequencing of the human genome in 2001. While at Celera, Peter led strategic alliances, acquisitions, and business strategy and helped launch it as a public company in 1999.

Prior to founding Celera, Peter held senior management positions at Applera, most recently serving as vice president of corporate planning and business development. During his tenure, he ran several businesses and expanded the life science business through a series of licensing agreements, partnerships, and acquisitions.

Peter is a member of the research council at Boston Children’s Hospital, and serves on the board of Perkin Elmer (NYSE:PKI).

Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program.
Chau Q. Khuong
Chau Quang Khuong has been at OrbiMed Advisors LLC since 2003 and is Private Equity Partner. Mr. Khuong gained experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He has been an active investor in drug development and medical device companies across many therapeutic areas and technology disciplines. He has been a Board of Directors representative at numerous OrbiMed investments, including currently Aerpio Therapeutics, Inc., Graybug Vision, Inspire Medical Systems, Intellia, Nabriva (NASDAQ: NBVR), NextCure, Otonomy, Inc. (NASDAQ: OTIC), Pieris Pharmaceuticals (NASDAQ: PIRS), and ReViral. Mr. Khuong holds a B.S. in molecular, cellular and developmental biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.
Nick Leschly
Nick Leschly is CEO of bluebird bio, Inc. (NASDAQ: BLUE) and has served in this role since September 2010. Previously, Nick was a partner and founding member of Third Rock Ventures in 2007. He played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc.

Prior to joining Third Rock, Nick worked at Millennium Pharmaceuticals, Inc., leading several early-stage drug development programs and served as the product leader for VELCADE.

Nick received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO).
Ed Mathers
Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Akouos, Ampylx Pharmaceuticals, Envisia Therapeutics, Inozyme, Liquidia Technologies, Lumos Pharmaceuticals, ObEva, Ra Pharmaceuticals, Reneo Pharma, Rhythm Pharmaceuticals, Senti Biosciences and Trevi Therapeutics. Previously, Ed was a director of Intarcia, Lumena (sold to Shire) Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo) and MedImmune,LLC.

Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.
Michael Powell, Ph.D.
Mike Powell is a General Partner of Sofinnova Ventures, a venture capital firm. Previously, he held positions at Genentech, Inc., Cytel Inc., a research and development company, and Syntex Research Group, a pharmaceutical company. Mike is currently a director of biopharmaceutical companies Galera Therapeutics, Dauntless Pharmaceuticals, Inc., Checkmate Pharma and Pionyr. He was previously Chairman of the Mirna Board of Directors from October 2012 until its merger with Synlogic in 2017. Dr. Powell is an Adjunct Professor at the University of Kansas and serves on the Washington University Board of Trustees in St. Louis. He received a B.S. in Chemistry from Scarborough College, a Ph.D. in Physical Chemistry from the University of Toronto and completed his post-doctorate work in Bioorganic Chemistry at the University of California.
Richard P. Shea
Rick Shea has served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. since February 2017. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Rick served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Rick received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University.